Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects
暂无分享,去创建一个
Ulf Bredberg | David Gustafsson | U. Bredberg | L. Johansson | Ulf G. Eriksson | U. Eriksson | Lars Frison | M. Ahnoff | L. Frison | D. Gustafsson | Kristina Gislén | Linda C. Johansson | Martin Ahnoff | Kristina Gislén
[1] D. Hosmer,et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. , 1991, Archives of internal medicine.
[2] B. Eriksson,et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial , 2002, The Lancet.
[3] B. Eriksson,et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. , 2002, Thrombosis and haemostasis.
[4] P. Held,et al. Pharmacokinetics and Pharmacodynamics of Melagatran, a Novel Synthetic LMW Thrombin Inhibitor, in Patients with Acute DVT , 1999, Thrombosis and Haemostasis.
[5] D B Matchar,et al. Incidence and occurrence of total (first-ever and recurrent) stroke. , 1999, Stroke.
[6] J. Hirsh,et al. New anticoagulant drugs. , 2001, Chest.
[7] A Abrahamsson,et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.
[8] M. Ahnoff,et al. Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[9] S. Pehrsson,et al. Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes , 1998, Thrombosis and Haemostasis.
[10] W M O'Fallon,et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.
[11] B. Eriksson,et al. Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. , 2002, Thrombosis research.
[12] P. Walker,et al. A population based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT Study. Anderson FA, Wheeler HB, Goldberg RJ, et al. Arch Intern Med 1991;151:933-8 , 1992 .
[13] J. Björkman,et al. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis , 1997 .
[14] S. Carlsson,et al. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. , 1999, Thrombosis research.
[15] E. Ohman,et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. , 2001, Chest.
[16] B. Eriksson,et al. A Dose-ranging Study of the Oral Direct Thrombin Inhibitor, Ximelagatran, and Its Subcutaneous Form, Melagatran, Compared with Dalteparin in the Prophylaxis of Thromboembolism after Hip or Knee Replacement: METHRO I , 2002, Thrombosis and Haemostasis.
[17] L. Tavazzi. Clinical epidemiology of acute myocardial infarction. , 1999, American heart journal.
[18] J. Deinum,et al. The Importance of Enzyme Inhibition Kinetics for the Effect of Thrombin Inhibitors in a Rat Model of Arterial Thrombosis , 1997, Thrombosis and Haemostasis.
[19] G. Agnelli,et al. The rationale for long-term prophylaxis of venous thromboembolism. , 2000, Orthopedics.
[20] M. Wolzt,et al. Inhibition of Thrombin Generation by the Oral Direct Thrombin Inhibitor Ximelagatran in Shed Blood from Healthy Male Subjects , 2002, Thrombosis and Haemostasis.
[21] J. Hirsh,et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. , 2001, Chest.
[22] J. Mehta,et al. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. , 1998, Journal of cardiovascular pharmacology.
[23] B. Eriksson,et al. Antithrombotic Effect of Two Low Molecular Weight Thrombin Inhibitors and a Low-Molecular Weight Heparin in a Caval Vein Thrombosis Model in the Rat , 1997, Thrombosis and Haemostasis.